See the full story in the original article.
Read the original on MarketWatch ↗
Keywords
Modernapharmaceuticalshealthcare
Open a keyword to see other news on the same topic.
Related news
- Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady
Moderna shares fell 7% to $185.74 in morning trading after its personalized melanoma vaccine, intismeran autogene, given with Keytruda, met its primary goal of reducing the risk of recurrence or death, but its effect on distant metastasis was far smaller than an earlier mid-stage study suggested. Detailed late-stage results were released on October 22 ahead of a conference in Madrid. BioNTech fell 3% to $85.65, Merck fell 0.2% to $145.61 and Pfizer fell 0.2% to $29.96, while the iShares Biotechnology ETF rose 0.2% to $208.21. The article notes Moderna's business relies entirely on mRNA medicines, so the vaccine carries a large share of its pipeline value, and says the next step is whether the full dataset supports a regulatory filing.
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Moderna's Stock Just Stumbled. Is It a Buy on the Dip?
Moderna shares fell 17% in one session after leaked data from a phase 3 trial of intismeran autogene combined with Merck's Keytruda, though the leaked results showed the drug combo cut the risk of recurrence or death by 42% in certain melanoma patients versus Keytruda alone, and by 58% after six months. The stock has still climbed more than 500% this year, trading near $200 versus an average Wall Street 12-month price estimate of $135. The author sees the dip as possibly a buying opportunity for long-term investors who want to open or add to a position, while cautioning that the stock remains sensitive to trial data and may see further pullbacks. Moderna currently has four commercialized products in the U.S., all respiratory vaccines.
- Moderna shares plunge after leak of partial cancer vaccine data despite positive results
Moderna shares fell as much as 25% on Thursday after partial data from its cancer vaccine developed with Merck leaked ahead of the full results, which were released later that day. The full data appeared positive relative to Wall Street expectations: the personalized vaccine intismeran autogene, combined with Keytruda, reduced the risk of recurrence or death in certain melanoma patients by 42% versus Keytruda alone, and cut the risk of distant spread or death by 38%. Detailed phase 3 results will be presented at the European Society for Medical Oncology conference this weekend. Investors view the vaccine as a possible breakthrough that could extend to other cancers, and the stock has spiked more than 530% this year on high expectations.
- Moderna's stock tumbles after reported leak of data for cancer vaccine
- Moderna is about to release the trial results for its cancer vaccine. A lot is riding on this data.
Related markets
Latest news
- Retiree Alleges Morgan Stanley Covered Call Strategy Cost Him His Apple and NVIDIA Shares; Reif Law Group Files Financial Elder Abuse Claims
Reif Law Group filed a petition in San Diego County Superior Court seeking FINRA arbitration against Morgan Stanley Smith Barney LLC and advisor Nicholas S. Westendorf on behalf of Michael J. Massery, a 77-year-old retiree. The petition alleges the firm placed him in a covered call strategy meant to protect his stock, then kept rolling the options for four years after he asked in writing to exit, until his Apple and NVIDIA shares were called away. Over more than 200 option transactions, the cost of exiting allegedly grew from about $434,000 to about $1 million. In December 2024, roughly 8,000 NVIDIA and 9,000 Apple shares were called away at strike prices far below market value, followed by a tax bill on the gains. The petition quotes an advisor's email stating the investor should have never been put into this strategy.
- Bretton Fund’s Views on Mobility Global (MBGL)
The Bretton Fund's Q3 2026 letter reports a -1.75% return for the quarter, versus +2.30% for the S&P 500. Microsoft and SAP were the strongest contributors, while Eagle Materials and Dream Finders Homes were hurt by a delayed housing recovery. The letter highlights Mobility Global (NYSE:MBGL), spun off from S&P Global at the start of July and renamed in February 2026, and says management judged its auto business to have little overlap with S&P Global's capital markets businesses. The stock closed at $18.76 on October 23, 2026, with a market capitalization of $5.53 billion, and returned 5.63% over the past month. Three hedge fund portfolios held it at the end of the second quarter, versus zero in the previous quarter.
- Elon Musk Warns Of 'Guppy-Level Death' For Hundreds of AI Cloud Firms. Others Are Not so Sure.
Elon Musk warned that more than 200 specialized AI cloud companies, known as neoclouds, could face widespread failures and consolidation as financing becomes harder to obtain. He said debt markets have almost entirely closed to firms without substantial revenue outside the AI data center business. CoreWeave and Nebius each lost more than 30% of their market value this month, and IREN fell about 40%, as the cost of insuring CoreWeave's debt against default rose sharply. Recent deals include CoreWeave's $4.2 billion convertible notes, a $3.5 billion Citi facility for Nebius and $2.8 billion in GPU financing for IREN. Nvidia and industry executives, however, say demand for computing power remains strong.
- JetBlue Airways Tumbles 16% as Creditors Hire Restructuring Advisers; United Airlines Rises 3%, Delta Edges Higher
JetBlue Airways shares fell 16% to $2.22 after a creditor group preparing for a possible restructuring hired restructuring advisers, according to a Wall Street Journal report; the group includes holders of senior bonds and a first-lien loan. Those bonds, backed by collateral tied to the loyalty program, have fallen to record lows. JetBlue has not commented on the hirings, and its CEO said in April the company was not considering bankruptcy this year. Meanwhile, United Airlines rose 3% to $100.75, Delta Air Lines rose 2% to $78.19, and the U.S. Global Jets ETF gained 0.8%. The article points to JetBlue's third-quarter 2026 report as the next key test.
- 98% Of Nvidia Analysts Have “Buy” Rating
Most analysts remain bullish on Nvidia: 54 of 55 on MarketBeat and 59 of 62 on Stock Analysis, a range of over 95% to 98%. The average price target is $325, versus a current price of $211, implying a potential rise of about 54%. The stock is up 725% over five years but has not beaten the S&P 500 this year. Revenue in the latest quarter rose 106% to $96 billion, yet skeptics such as Apollo economist Torsten Slok argue AI spending has delivered no financial payoff outside tech. Critics also say Nvidia's demand partly depends on its investments in its own chip customers, and by one count, communities opposed to data centers have delayed 200 of them this year.
- South Korea weighs fourth delay on its crypto gains tax, pushing it to 2029
South Korea is leaning toward delaying its crypto gains tax, due to start in January, until 2029, which would be a fourth postponement. Officials are concerned that users of domestic exchanges would bear most of the burden because the U.S. will not share crypto trading data until 2029, and one official said almost half the crypto market is in the U.S. Deputy Prime Minister Koo Yun-cheol had said in July the tax would take effect in January 2027, but his successor, Lee Hyung-il, said he would gather views from parliament, experts and industry. Under current rules, annual net income from crypto transfers or lending is taxed at 20%, or 22% including local income tax, after a 2.5 million won ($1,887) deduction. Parliament must approve the change, with a final decision expected by early December.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.